https://t.co/3XLYTgAnSV via @yumpu_com
#Moduloft The Concept. #Cop26 Draft No.1 Presentation and discussion #BuildBackBetter #LevellingUp

Israel in Egypt - Handel - Downtown Voices and Trinity Baroque Orchestra... https://t.co/tKoopO1paE via @YouTube Plagues and Census' Old and New Testaments to #CovidPurpose #Covid19Aphorism Narrative by Aphorism #ArrestHancock

https://t.co/kWHHSWdlw2 #GoldStandard #Bitcoin #BTC
#Covidstroika

2020 marks the start of the quantum dot revolution.

Completely ignoring the fact that "photocatalytic generation of reactive oxygen species (ROS) from quantum dots (QDs) has been widely reported."

Results: It was found that whereas singlet oxygen (1O2) was not produced by photoexcited QDs, superoxide anion(O2− )and hydroxyl radicals(OH) were generated by QDs, especially in the presence of a physiological concentration of electron donating agent including NADH.

Using cell metabolic activity assays and various probes of ROS generation, the formation of ROS in cellular environments was demonstrated.

Conclusion: Illumination of QD-treated cells and bacteria with light did affect viability. The above results, together with those of assays in the presence of various scavengers of specific ROS, indicate that the formation of ROS by QDs mainly proceeded via electron transfer.

#SuvenLife – Niche R&D play..very high risk and very high reward…key is right allocation…

Jazz Pharma was quoting around $0.5 in 2009, today its $150 and Mcap of $8.5 Bn on Nasdaq..almost 300x in 11 years. 80% of its total sales ($2.1 Bn) come from single drug Xyrem.

Axovant Lifescience, bought Alzheimer molecule from GSK, repackaged it and done phase-3 trials. Before starting the trials, the valuation was $2 Bn, just before announcing the data, it rose to $3 Bn. One of the leading broker put the target of $12 Bn if the trials succeeded..

but it failed in phase-3 trials. Current Mcap is $120 Mn…

This is R&D for New Chemical Entity (NCE)…very high risk and very high reward…

Brain-related illnesses, also known as CNS diseases, afflict more than 2 billion people worldwide. Diseases of the brain and mind range

from Alzheimer’s, dementia, epilepsy, migraine, multiple sclerosis, neuro infections, Parkinson’s, psychosis, schizophrenia and stroke to brain injuries and various mental disorders. The global market or CNS therapeutics is projected to reach $137.7 billion by 2025.

#SuvenLife has 1 lead molecule SUVN-G3031 in phase-2 trials which is similar to Xyrem but superior features, 3 molecules completed phase-1 trials and starting phase-2 trials and 11 molecules in pre-clinical trials. All are related to CNS which is growing and uncluttered market

There's a particular kind of romantic partnership, with a certain sort of person, that I've wanted since I became a self-aware, directed agent at around age 15.

Empirically, this kind of relationship has been hard to achieve. It hasn't worked out yet, at least.

And this sometimes leaves me wondering if my standards are unreasonable.

In years past that desire was often very alive.

These days, I'm rarely directly or viscerally in contact with it.

I sometimes contemplate aiming for some other kind of romantic and/or sexual relationship instead. In part because I might be more effective if I...I don't know, got laid more? But that's not really the thing. More like, if I had someone around whom I could regularly relax.

But mostly, I don't pursue those alternative relationship-setups out of a sense of something like loyalty to myself + a vague sense of wrongness and/or sadness about it. It often feels like giving up or giving in.

[I might elaborate on the wrongness sometime.]